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Risperidone non-compliance is often high due to undesirable side effects,
whose development is in part genetically determined. Studies with genetic
variants involved in the pharmacokinetics and pharmacodynamics of
risperidone have yielded inconsistent results. Thus, the aim of this study
was to investigate the putative association of genetic markers with the
occurrence of four frequently observed adverse events secondary to
risperidone treatment: sleepiness, weight gain, extrapyramidal symptoms
and sexual adverse events. A series of 111 schizophrenia inpatients were
genotyped for genetic variants previously associated with or potentially
involved in risperidone response. Presence of adverse events was the main
variable and potential confounding factors were considered. Allele 16Gly of
ADRB2 was significantly associated with a higher risk of sexual adverse events.
There were other non-significant trends for DRD3 9Gly and SLC6A4 S alleles.
Our results, although preliminary, provide new candidate variants of
potential use in risperidone safety prediction.
The Pharmacogenomics Journal (2013) 13, 197–204; doi:10.1038/tpj.2011.57;
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Introduction
Since 1959 when Vogel coined the term pharmacogenetics, there is increasing
evidence that therapeutic outcome is influenced genetically.1 One of the most
important applications might be schizophrenia management because of the high
prevalence of this illness (1% approximately across countries and cultures) and
the non-compliance often seen with the antipsychotic treatment.2 Risperidone is
a widely prescribed antipsychotic for the treatment of schizophrenia, with a
relatively high rate of non-effectiveness or intolerable side effects.2 In fact,
extensive research has been devoted to elucidate the genetic underpinnings of
risperidone response to reduce its adverse effects.3
Risperidone pharmacogenetic studies have focused on clinical improvement
and adverse events, such as the frequently observed extrapyramidal symptoms
(EPS),4 hyperprolactinemia,5 hyperlipidemia,6 weight gain7 and metabolic
syndrome.8 Candidate genes to be involved in the above mentioned events
have been CYP2D6 and MDR1, related to pharmacokinetics and DRD2,9 DRD3,4
HTR2A or HTR2C,7 all of them coding risperidone targets. Additionally, others
like BDNF,7 COMT,10 HTR1A,11 HTR67 or LEP12 have been explored in relation
with risperidone effectiveness or side effects. However, all of them have yielded
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conflicting results, so no definitive genetic marker predic-
tive of risperidone response exists currently.
Thus, the aim of this study was to examine the putative
association of several genetic markers related to risperidone
pharmacokinetics and pharmacodynamics or potentially
involved, with four of the most frequent and discomforting
adverse events secondary to risperidone treatment (sleepi-
ness, weight gain, EPS and sexual dysfunction)2 in a sample
of acutely ill schizophrenic inpatients.
Subjects and methods
Subjects
As a part of a larger pharmacogenetic schizophrenia project,
111 acutely ill schizophrenic patients were recruited at
the Department of Psychiatry of Fundacion Jimenez Diaz
Hospital between 2004 and 2009. All subjects were adult
patients hospitalized in an Acute Psychiatric Unit, unrelated
and Caucasian. DSM-IV diagnosis was obtained by means of
a brief structured psychiatric interview, the Spanish version
of the Mini International Neuropsychiatric Interview version
4.4 (MINI 4.4).13 The study was approved by the Research
Ethics Committee of Fundacion Jime´nez Dı´az Hospital and
conducted according to the tenets of the Declaration of
Helsinki. All participants signed an informed consent form
after the explanation of the study objective and procedures.
Clinical data
All subjects were inpatients with variable length of hospital
stay. They were all treated with risperidone. Treatment
dosage was established according to patient’s clinical state.
Concurrent treatments, such as other antipsychotics, anti-
cholinergics, antidepressants, antiepileptics or benzodiaze-
pines, were used. Sex, age, risperidone dosages, length of
hospitalization and concomitant treatments were consid-
ered as potential confounding factors for the association
with the genetic variants. The main variables, sleepiness,
weight gain, EPS and sexual adverse events, were assessed
with the UKU scale14 at the hospital discharge by psychia-
trists trained in the UKU evaluation.
Variant selection and genotyping
Genomic DNA was extracted from 7 ml of peripheral blood
samples using an automatic DNA extractor (BioRobot EZ1,
Qiagen, Hilden, Germany). Genes, variants and the ratio-
nale for the selection are summarized in Table 1. All genetic
variants investigated were either previously related to
risperidone outcome or potentially involved (Table 1). Some
of them were included in PHARMAChip,15 a commercially
available tool whose suitability in pharmacogenetic geno-
typing has been previously described,16,17 and others
were determined by allelic discrimination or sequencing
(Table 1). Allelic discrimination was performed using Taq-
Man Pre-Designed SNP genotyping assays (Applied Biosys-
tems, Foster City, CA, USA) in a LightCycler 480 (Roche
Diagnostics, Mannheim, Germany). Sequencing was used to
genotype BDNF Val66Met and to verify the truth-
fulness of the allelic discrimination results with a BigDye
Terminator Cycle Sequencing Kit and an ABI Prism 3130xl
DNA sequencer (Applied Biosystems). Primer sequences and
conditions are available upon request.
Data and statistical analysis
All genetic variants were tested for Hardy–Weinberg equili-
brium (HWE) deviation using Pearson Chi-squared test (w2).
The association of the genetic variants with the dependent
variable was performed through the codominant genetic
model in all cases except CYP2D6, whose genotypes were
grouped based on the number of functional alleles into poor
metabolizers (two defective alleles), intermediate metaboli-
zers (one defective allele), extensive metabolizers (two
functional alleles) and ultra rapid metabolizers (more than
two functional alleles), according to a previous report by
Gaedigk et al.31
The presence of all four adverse events (sleepiness, weight
gain, EPS and sexual adverse events), notwithstanding their
severity, was the main variable. EPS category consisted of
the UKU items akathisia, hyperkinesia, hypokinesia, rigidity
or tremor. The sexual adverse event category included the
following items: diminished sexual desire, dry vagina and
erectile, ejaculatory and orgasmic dysfunctions. For both
EPS and sexual adverse effects, ‘presence’ was considered as
the occurrence of at least one of the signs or symptoms.
For continuous variables, mean and standard deviations
were calculated and also data distributions were tested for
normality. In case of non-adjustment, they were categorized
for the statistical analysis.
Logistic regression was used to examine the association of
the genotypes with the presence of the adverse events,
adjusting for covariates. The strength of the association was
measured with the odds ratio (OR) and its 95% CI
(confidence interval). The effect of the genetic variant on
the outcome was adjusted by those demographic and
clinical variables (covariates) either associated with the out-
come (Po0.05) or modifying the risk (change in putative
OR420%) of the genetic variant on the outcome. Hence,
the effect of the covariates on the risk to develop the adverse
events was also investigated.
Because of the multiple testing, Bonferroni correction was
applied and the cutoff value was set as Pp0.003 (P¼0.05/19
hypothesis tested).
Statistical analysis was carried out using the STATA v10
software (Stata Corp, TX, USA).
Results
Clinical and genetic data
None of the continuous variables were normally distributed,
so they were categorized for the analysis as shown in Table 2.
Age of the patients (45±13 years) was grouped into o40
years, 40–59 years and X60 years; and length of hospital
stay (13±9 days) was transformed considering the median
of data distribution (12 days).
Patients were prescribed oral (mean dosage¼ 8.1±3.3 mg)
and intramuscular (25–100 mg biweekly) risperidone. 73%
(n¼81) were taking oral risperidone, 6.3% intramuscular
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(n¼7) and 20.7% were taking both forms (n¼23). Risper-
idone dosages were grouped according to the terciles of data
distribution (11 missing data), if administered orally, and in
three categories in the case of intramuscular administration
(2 missing data). Concomitant treatments were classified
according to the therapeutic group (Table 2).
All genetic variants investigated were in HWE except
ADRB2 16Gly (P¼0.002). When grouping CYP2D6 accord-
ing to the number of defective alleles, 3 subjects were
classified as poor metabolizers and 3 as ultra rapid
metabolizers (0.294), 32 as intermediate metabolizers
(0.314) and 64 as extensive metabolizers (0.628) (there
were 9 subjects, which genotype was missing). For the
X chromosome HTR2C 759C4T variant, CC accounted for
84 subjects (0.764) and allele T was present in 26 patients
(0.236) (1 genotype was missing). Genotype frequencies of
the remaining variants are summarized in Table 3. In one
sample, no genotyping results for the PHARMAChip
variants could be obtained because of the low quality of
the DNA. Additionally, there were 5 missing genotypes for
SLC6A4, also included in the array. For variants determined
by allelic discrimination, there were 4 missing genotypes for
ADRA1 4884G4A, 9 for BDNF Val66Met and 3 in case of
HTR1A 1019C4G.
Regarding the four adverse events investigated, the most
frequent was sleepiness in 66 patients (56.7%), weight gain
and EPS were observed in 40 patients each (36%) and 25
patients had sexual adverse events (22.5%).
Table 1 Genetic variants included in the pharmacogenetic study
Gene Gene name Genetic variant Function Previous associationsref.
Pharmacokinetics
CYP2D6a Cytochrome P450 2D6 *1, *2, *3, *4, *5, *6,
*7, *8, *9, *10, *11, *14,
*15, *17, *19, *20, *25,
*26, *29, *30, *31, *35,
*40, *41; *1XN, *2XN,
*4XN, *10XN, *17XN,
*35XN, *41XN
Risperidone metabolism Risperidone plasma levels,
effectiveness and adverse
events18,19
CYP3A4a Cytochrome P450 3A4 *1B Risperidone metabolism Risperidone plasma levels and
effectiveness20
MDR1a Multidrug resistance 1 3435C4T Risperidone active
transporter
Risperidone induced adverse
events and response21,22
Pharmacodynamics
ADRA1b Adrenergic receptor a1 4884A4G
4155C4G
563C4T
Risperidone target Atypical antipsychotic response
(negative findings)23
ADRB1a
ADRB2a
Adrenergic receptor 1
Adrenergic receptor 2
Arg389Gly
Arg16Gly
Members of the adrenergic
pathway
Potentially involved in risperidone
response
BDNFb Brain-derived neurotrophic
factor
Val66Met Related to serotonin
pathway
Risperidone effectiveness and
adverse events7,24
COMTa Catechol-o-Methyl
transferase
Val108Met Member of dopaminergic
pathway
Risperidone effectiveness25
DRD2b Dopamine receptor D2 Taq1A Risperidone target Risperidone effectiveness and
adverse events9,26
DRD3a Dopamine receptor D3 Ser9Gly Risperidone target Risperidone effectiveness and
adverse events4,27
GRIN2Ba Glutamatergic receptor 2B 2667C4T Member of glutamatergic
pathway
System previously associated to
risperidone outcome28
HTR1Ab Serotonin receptor 1A 1019C4G Member of serotoninergic
pathway
Effectiveness (negative findings)26
HTR2Aa Serotonin receptor 2A 102C4T
His452Tyr
Risperidone target Effectiveness and adverse
events27,29
HTR2Cb Serotonin receptor 2C 759C4T Risperidone target Effectiveness and adverse events27
HTR6b Serotonin receptor 6 267T4C Risperidone target Effectiveness and adverse events27
SLC6A4a Serotonin transporter Promoter VNTR Member of serotoninergic
pathway
Effectiveness30
Abbreviation: VNTR, variable number tandem repeat.
aGenotyped with PHARMAChip genotyping array.
bAllelic discrimination or sequencing.
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Genetic associations with adverse events
When the genotype significantly associated with the out-
come was the heterozygous one, dominant genetic model
was also evaluated. The only association that remained
significant after Bonferroni correction was that of ADRB2
16Gly as a risk factor for developing risperidone-induced
sexual adverse events (Table 4). Furthermore, as shown in
Table 4, there were also some non-significant trends: DRD3
9Gly was present with a higher incidence in those patients
who developed risperidone-induced sleepiness and, conver-
sely, it appeared less frequently in patients with EPS.
Additionally, allele S of SLC6A4 was underrepresented in
patients with weight gain (S/S) and also in those with sexual
adverse events (L/S).
Besides considering the demographic and clinical vari-
ables as potential confounding factors, it was also evaluated
whether they could influence the development of the four
adverse events investigated. Only anticholinergic consump-
tion was associated with a higher incidence of weight gain
(OR¼3.28; 95% CI: 1.02–10.54; P¼ 0.046).
Discussion
The present study sought to evaluate the possible associa-
tion of genetic variants related to risperidone pharmaco-
kinetics and pharmacodynamics, and others with potential
involvement, with the risk of developing four of the most
frequent adverse events secondary to risperidone treatment.
The investigation of the genetic basis of risperidone safety
has traditionally focused on weight gain and EPS, consid-
ered as the most handicapping adverse effects.32 However, to
our knowledge, no report has examined sleepiness or sexual
Table 2 Frequency of patients according to the demographic
and clinical variables
Variable Category n (%)
Sex Males 62 (55.8)
Females 49 (44.2)
Age o40 years 38 (34)
40–59 years 61 (55)
X60 years 12 (11)
Hospital stay p12 days 57 (62)
412 days 35 (38)
Oral risperidone dosages o6mg per day 44 (47)
6–9mg per day 28 (30)
49mg per day 21 (23)
Intramuscular 0mg 81 (73)
risperidone dosages o50mg per 2 weeks
X50mg per 2 weeks
9 (8.1)
19 (17.1)
Concomitant treatments Anticholinergics 21 (21)
Antidepressants 10 (9)
Antiepileptics 12 (10.8)
Atypical antipsychotics 7 (6.3)
Benzodiazepines 54 (48.6)
Classical antipsychotics 12 (10.8)
Lithium 2 (1.8)
There were missing data for hospital stay (19) and risperidone dosages (11 for oral
and 2 for intramuscular).
Table 3 Allelic and genotypic frequencies of the genetic variants investigated
Allele (N(p)) Genotype (N (p))
Genetic variant A B AA AB BB
ADRA1 563C4T 123 (0.554) 99 (0.446) 33 (0.297) 57 (0.513) 21 (0.189)
ADRA1 4155C4G 109 (0.491) 113 (0.509) 26 (0.234) 57 (0.514) 28 (0.252)
ADRA1 4884A4G 167 (0.780) 47 (0.220) 65 (0.607) 37 (0.346) 5 (0.047)
ADRB1 Arg381Gly 58 (0.264) 162 (0.736) 10 (0.091) 38 (0.345) 62 (0.564)
ADRB2 Arg16Gly 169 (0.768) 51 (0.232) 75 (0.682) 19 (0.173) 16 (0.145)
BDNF Val66Met 161 (0.789) 43 (0.211) 65 (0.637) 31 (0.304) 6 (0.059)
COMT Val108Met 116 (0.527) 104 (0.473) 29 (0.264) 58 (0.527) 23 (0.209)
CYP3A4 *1B 116 (0.527) 104 (0.473) 6 (0.054) 104 (0.945) 0 (0.000)
DRD2 Taq1A 181 (0.815) 41 (0.185) 75 (0.676) 31 (0.279) 5 (0.045)
DRD3 Ser9Gly 147 (0.668) 73 (0.332) 48 (0.436) 51 (0.464) 11 (0.100)
GRIN2B 2664C4T 174 (0.791) 46 (0.209) 69 (0.627) 36 (0.327) 5 (0.045)
HTR1A 1019C4G 103 (0.477) 113 (0.523) 29 (0.268) 45 (0.417) 34 (0.315)
HTR2A His452Tyr 196 (0.891) 24 (0.109) 86 (0.782) 24 (0.218) 0 (0.000)
HTR2A 102C4T 123 (0.559) 97 (0.441) 38 (0.345) 47 (0.427) 25 (0.227)
HTR2C 759C4T 179 (0.821) 39 (0.179) 80 (0.734) 19 (0.174) 10 (0.092)
HTR6 267C4T 188 (0.847) 34 (0.153) 81 (0.730) 26 (0.234) 4 (0.036)
MDR1 3435C4T 113 (0.514) 107 (0.486) 34 (0.309) 45 (0.409) 31 (0.282)
SLC6A4 L/S 126 (0.613) 86 (0.387) 38 (0.358) 50 (0.472) 18 (0.170)
A refers to wild-type allele and B to the mutant one. For HTR2C 759C4T AA¼CC (females)+C (males); AB¼CT (females) and BB¼ TT (females)+T (males).
N¼Absolute frequency and P¼ relative frequency.
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adverse events, which are reported by patients to be as
frequent and discomforting as the formers.2
This pharmacogenetic study describes for the first time
the association between ADRB2 16Gly and a greater
susceptibility of developing sexual adverse events in schizo-
phrenic patients under risperidone treatment, considering
potential demographic and clinical confounding factors.
The elevated frequency of sexual dysfunction among
schizophrenia patients treated with antipsychotics has been
reported to reduce patients’ quality of life.33 Even though
the incidence of these adverse events can reach as much as
50% of patients and that usually lead to treatment non-
compliance,33 to our knowledge no pharmacogenetic study
concerning sexual adverse events secondary to risperidone
therapy has been performed until date. Sexual normal
function involves several neurotransmitter systems, such
as dopaminergic, adrenergic and serotoninergic, involved in
processes like erection, ejaculation and orgasm.34 Therefore,
the disruption of any of these systems might lead to sexual
side effects and would support our findings about ADRB2
16Gly as a risk factor, which has been linked to lower b2
adrenergic receptor density and efficiency.35 It should be noted
that although ADRB2 16Gly did not meet HWE it was not
removed from the study to prevent from the possibility of
being out of HWE because of a linkage with the disease. All
patients were ascertained by their disease status and so, the
subject selection was not random, which is one of the premises
of HWE for genotypic frequencies to reach a fixed value.
We are aware that genotyping errors should also
be considered as a cause of HWE departure. In this
regard, two relatively recent reports have demonstrated the
accuracy of PHARMAChip in genotyping, one of them
performed by our group.16,17 Nevertheless, our previously
mentioned study also reports this variant deviating from
HWE in the Spanish control population.16 However, it has
been demonstrated that this typically occurs in several
European populations, suggesting this variant is subject to
selective forces, such as parental selection or epistasis,
leading to oscillations in genotype frequencies.36
Therefore, considering all the above explanations,
although preliminary, this result should be taken into
account and be further validated in an independent sample.
Although ADRB2 16Gly was the only variant that met
Bonferroni cutoff value, there were some non-significant
trends that should be highlighted. Although multiple
comparison adjustment is necessary in order to avoid type-I
error, it significantly increases type II and therefore the
likelihood of false negatives, and Bonferroni correction is
especially conservative in this regard. The consequence of the
adjustment is a decrease in the statistical power, which was
already low because of the population sample size, and the
increase in the rate of false negative findings. Indeed,
for the association of the event with the higher incidence
and the genotype with the higher frequency, it is only
possible to detect, with 80% statistical power, ORs greater
than 4 (or lower than 0.25), which is higher than expected. It
is suggested that the risk that genetic variants confer to the
complex phenotypes, such as risperidone response, range
from low to moderate.37 In consequence, it would require
substantially larger sample sizes to detect associations with
lower ORs, for genotypes with lower frequencies or for
adverse events with lower incidence. In any case, the study
was performed through a candidate gene approach, where
the rationale for the variant selection was to be linked to
risperidone pharmacokinetic and/or pharmacodynamic path-
ways. Additionally, among all possible variants, we chose
from the literature those with the higher likelihood of being
involved in the occurrence of the outcomes, because of the
existence of previous positive findings. Hence, given that the
study was hypothesis-driven and due to the small sample size
of the population included, the non-significant trends found
should not be completely ruled out, but considered as
exploratory findings that need to be further confirmed.
One of those non-significant trends was the higher
incidence of sleepiness in patients carrying allele 9Gly of
DRD3. DRD3 Ser9Gly variant has been extensively studied
with regard to many antipsychotics’ effectiveness and safety,
but with inconsistent results.38,39 In the present study, the
higher propensity observed to sleepiness among patients
with the DRD3 9Gly allele suggests that disruption of the
dopaminergic neurotransmission might contribute to the
sleep disturbances experienced by schizophrenic patients, as
it is well established that dopaminergic system participates
in the wake–sleep cycle.40 Conversely, the same allele was
linked to a lower incidence of EPS. Although the atypical
antipsychotics are known to be safer concerning motor side
effects compared with the classical ones, risperidone treat-
ment is known to have a relatively high rate of EPS.32
Table 4 Association of the genetic variants with the adverse events
Adverse event (n (%)) Genetic variant Genotypic frequencies (n (%)) OR (95% CI) P
Cases Controls
Sexual adverse events ADRB2 16Gly 14 (56%) 21 (25%) 4.58 (1.72–12.20) 0.002*
(25 (22.5%)) SLC6A4 L/S 6 (25%) 44 (53.6%) 0.22 (0.06–0.75) 0.015
Sleepiness (66 (56.7%)) DRD3 9Gly 40 (64.5%) 22 (45.8%) 2.47 (1.00–6.09) 0.050
EPS (40 (36%)) DRD3 9Gly 18 (45%) 44 (62.8%) 0.29 (0.11–0.79) 0.015
Weight gain (40 (36%)) SLC6A4 S/S 1 (2.7%) 17 (24.6%) 0.07 (0.01–0.66) 0.020
Significant findings (*; Po0.003) and non-significant trends (Po0.05) from the genetic association study after adjusting with the potential confounding variables.
*Po0.003.
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Whereas data on the possible relevance of the Ser9Gly
variant of DRD3 in EPS are still controversial,4,41 our study
reports a trend to a protective effect of the 9Gly allele. That
effect could be explained by the role that D3 receptors have
in motor control,42 with their agonists exerting an inhibi-
tory effect.43 This, together with the higher affinity and
effectiveness that dopamine shows for D3 receptors with the
9Gly variant44 could be in line with the observed effect.
On the other hand, patients carrying the SLC6A4 S/S geno-
type were less likely to gain weight secondarily to risperidone
treatment. Currently, there is an increasing concern regarding
weight gain in schizophrenia patients, as it significantly
impacts the antipsychotic compliance.45 Although the exact
mechanism for antipsychotic-related weight gain remains
unclear, the serotoninergic system has emerged as a strong
candidate.45 Specifically and based on the large body of
evidence that supports the role of serotonin in regulating
feeding behavior, variants in genes involved in serotoninergic
neurotransmission, such as HTR2A, HTR2C, HTR6 or BDNF,
have been previously associated with weight gain secondary to
risperidone treatment.7 Despite our failure to replicate the
above-mentioned associations, the lower incidence of weight
gain in SLC6A4 S/S carriers is in consonance with the recent
report by Bah et al.,46 who found this genotype to be more
prevalent in underweight control individuals.
Further, the L/S genotype was observed to predispose
patients to lower incidence of sexual adverse events. As
previously mentioned, the serotoninergic system partici-
pates in normal sexual function and so carrying the SLC6A4
short allele could protect patients from developing sexual
dysfunction secondary to risperidone treatment.
Overall, none of the previous associations were replicated.
Strikingly, variants in CYP2D6 and MDR1, which have been
reported to influence risperidone plasma concentrations18,47
did not yield significant results. CYP2D6 is involved in the
hydroxylation of risperidone to 9-OH risperidone47 and there
is increasing evidence about the correlation between the
number of functional CYP2D6 alleles and both risperidone
and 9-OH risperidone plasma concentrations.18,47 Similarly,
MDR1, involved in risperidone transportation through the
blood–brain barrier,48 has been several times associated with
risperidone plasma concentrations,49 effectiveness and
safety.21,22 MDR1 encodes P-glycoprotein, a drug transporter
that works limiting risperidone entry to the brain.50 The
3435T allele of MDR1 results in lower P-glycoprotein
expression,51 which may result in higher brain risperidone
concentrations. According to their role in risperidone
pharmacokinetics, it was expected for CYP2D6 and MDR1
to impact significantly the development of adverse events.
However, once again, the small sample size studied could
have been responsible for the negative findings.
The non-replication and the lack of association found for
most of the genetic variants investigated point out the
complexity of risperidone response, which is determined by
the interaction of several genetic and environmental
factors37 and whose contribution to the antipsychotic
response is difficult to establish. In addition, there are other
factors, intrinsic to psychiatric patients management, and
hence, to pharmacogenetic studies on antipsychotics, that
makes complex the search of the genetic basis of drug
response. Such factors are the uncertainty of the psychiatric
phenotype, the variety of treatments administered in
psychiatric patients and the large number of confounding
factors affecting the antipsychotic response, what conforms
a heterogeneous subject sample. All these factors, typically
common to all pharmacogenetic studies on antipsychotics,
together with the small sample size here investigated, could
have been responsible for the negative findings yielded in
this study and for the general inconsistencies of pharmaco-
genetic studies in schizophrenia. The consequence is the
inexistence of a definitive predictive factor of risperidone
response until date.
In conclusion, although further replication in an inde-
pendent sample with adequate statistical power is needed,
this study provides new candidate genetic variants of
potential use in risperidone safety prediction. Additionally,
it points out the importance adrenergic, dopaminergic and
serotoninergic disruption might have in the risk of devel-
oping four of the most handicapping adverse events secon-
dary to risperidone treatment, namely sleepiness, weight
gain, EPS and sexual adverse events.
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